Does C-reactive protein add prognostic value to GRACE score in acute coronary syndromes?

Area of Science:

• Cardiology
• Biomarkers
• Clinical Prognostics

Background:

• The prognostic utility of C-reactive protein (CRP) in acute coronary syndrome (ACS) with non-ST segment elevation, relative to the GRACE score, remains unclear.
• Assessing novel biomarkers alongside established risk scores is crucial for refining patient management.

Purpose of the Study:

• To evaluate whether plasma CRP levels at admission enhance the prognostic value of the GRACE score in ACS patients.
• To determine if CRP provides incremental predictive information beyond the GRACE score for in-hospital cardiovascular events.

Main Methods:

• A cohort of 290 ACS patients had plasma CRP measured using high-sensitivity nephelometry upon admission.
• Cardiovascular outcomes included in-hospital death, nonfatal myocardial infarction, or refractory angina.
• Statistical analyses assessed CRP's predictive performance and its incremental value when added to the GRACE score.

Main Results:

• The incidence of in-hospital cardiovascular events was 15%.
• Elevated CRP showed a trend towards association with hospital events after GRACE score adjustment (OR = 1.89, p = 0.08).
• Adding CRP to the GRACE model did not significantly improve C-statistics (0.705 to 0.718, p = 0.46) or risk reclassification (5.7%, p = 0.15).

Conclusions:

• While C-reactive protein (CRP) is linked to adverse hospital outcomes in ACS patients, it does not augment the prognostic capabilities of the GRACE score.
• The GRACE score alone appears sufficient for risk stratification in this patient population, without added benefit from CRP.